Schrodinger (SDGR) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Schrodinger (SDGR) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 39.2% versus a loss of 8.6%. Over five years, STOK leads with a +6.8% price change compared with -42.0% for SDGR. Stoke Therapeutics is the larger company by market cap ($1.75 billion vs $1.72 billion), about 1.0 times the size.
Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -40.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | STOK |
|---|---|---|
| Share price | $22.93 | $26.81 |
| Market cap | $1.72B | $1.75B |
| 1-day change | -12.95% | -0.45% |
| YTD return | +28.24% | -15.53% |
| 1-year return | +39.22% | -8.62% |
| 5-year return | -42.01% | +6.77% |
| EPS (TTM) | $-0.79 | $-3.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $255.87M | $184.42M |
| Revenue growth (YoY) | +23.29% | +404.50% |
| Net income (latest FY) | $-103.27M | $-6.88M |
| Gross margin | 55.74% | — |
| Operating margin | -65.23% | -11.16% |
| Net margin | -40.36% | -3.73% |
| 52-week high | $34.00 | $40.22 |
| 52-week low | $10.95 | $22.05 |
| Distance from 52-week high | -32.56% | -33.34% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +46.40% | +73.00% |
| Average volume | 2.08M | 1.02M |
| Shares outstanding | 65.91M | 65.41M |
| Employees | 850 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed STOK by 47.8 percentage points over the past year.
- Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -40.4 cents for Schrodinger.
- Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +23.29%).
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
SDGR vs STOK FAQ
Which is bigger, Schrodinger or Stoke Therapeutics?
Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.75B compared with $1.72B for Schrodinger (SDGR).
Which stock has performed better over the past year, SDGR or STOK?
SDGR returned +39.22% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.